Trinity Biotech (TRIBY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY)

TRIB 0.808

-0.9%

Feb 2 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: whynag	2/4/2006 2:50:59 AM
	Read Replies (1) of 14328

Davy Stockbrokers Dublin Trinity Biotech (TRIB US) White House commitment to rapid HIV testing Previous close: $8.59 Target: $8.40 (29/04/05) Analyst: jack.gorman@davy.ie Trinity Biotech may potentially benefit from additional state funding earmarked for the purchase and distribution of rapid HIV test kits in the US market. The company is one of only a handful of rapid test manufacturers in the US, with Orasure the clear market leader at present. Additional sector funding would help support our own 2006/2007 forecasts which anticipate that US sales of Trinity’s rapid HIV test more than double from estimated 2005 levels. The US president, in his state of the union address, proposed to direct more than $90m to the purchase and distribution of kits for more than 3m Americans. $20m of this is specifically targeted at routine testing in US prisons, and another $20m will be used for healthcare professionals who most often come into contact with high-risk groups such as intravenous drug users.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next